SCHEMBL11029225

SCHEMBL11029225

C=CC(C)CCCC(C)(C)OC

nearest known ligand 0.38

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.38
ALDH1A1 P00352 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
LMNA P02545 1/20 0.38
MEN1 O00255 1/20 0.34
ALOX15 P16050 1/20 0.34
KMT2A Q03164 1/20 0.34
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1171382 0.82 ALDH1A1 (0.39) CYP3A4ALDH1A1TDP1LMNATSHR
SCHEMBL29619785 0.80 ALDH1A1 (0.41) CYP3A4ALDH1A1TDP1LMNATSHR
SCHEMBL225537 0.80 ALDH1A1 (0.41) CYP3A4ALDH1A1TDP1LMNATSHR
SCHEMBL11075172 0.79 MEN1 (0.32) CYP3A4MEN1ALOX15KMT2A
SCHEMBL569847 0.79 TDP1 (0.32) CYP3A4TDP1MEN1ALOX15KMT2A
SCHEMBL27959568 0.79 MEN1 (0.35) CYP3A4MEN1ALOX15KMT2ATSHR
SCHEMBL11075175 0.79 MEN1 (0.32) CYP3A4MEN1ALOX15KMT2A
SCHEMBL17710673 0.79 MEN1 (0.32) CYP3A4MEN1ALOX15KMT2A
SCHEMBL19812429 0.79 CYP3A4 (0.36) CYP3A4ALDH1A1TDP1LMNAMEN1
SCHEMBL158257 0.78 GAA (0.37) CYP3A4ALDH1A1TDP1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4662194-A1 NEW METHOD FOR OZONOLYSIS AND REDUCTIVE QUENCHING OF OZONIDES P2 Science, Inc. (US) 2025-12-17 EP claimed
WO-2024167957-A1 NEW METHOD FOR OZONOLYSIS AND REDUCTIVE QUENCHING OF OZONIDES P2 SCIENCE, INC. (US) 2024-08-15 WO claimed
WO-2018145219-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING SERANI MOSTAZAL JORGE (CL) 2018-08-16 WO claimed
EP-4662194-A1 NEW METHOD FOR OZONOLYSIS AND REDUCTIVE QUENCHING OF OZONIDES P2 Science, Inc. (US) 2025-12-17 EP disclosed
CN-119798050-A Method for synthesizing santalol ether from methoxy citronellene 万华化学集团股份有限公司 2025-04-11 CN disclosed
WO-2024167957-A1 NEW METHOD FOR OZONOLYSIS AND REDUCTIVE QUENCHING OF OZONIDES P2 SCIENCE, INC. (US) 2024-08-15 WO disclosed
EP-3927688-B1 PROCESS FOR PERHYDROLYSIS OF ALIPHATIC EPOXIDES DEMETA (FR) 2024-01-31 EP disclosed
US-11512050-B2 Process for perhydrolysis of aliphatic epoxides DEMETA (FR) 2022-11-29 US disclosed
US-20220169601-A1 PROCESS FOR PERHYDROLYSIS OF ALIPHATIC EPOXIDES UNIVERSITE DE RENNES (FR) 2022-06-02 US disclosed
EP-3927688-A1 PROCESS FOR PERHYDROLYSIS OF ALIPHATIC EPOXIDES Demeta (FR) 2021-12-29 EP disclosed
CN-113614067-A Process for perhydrolysis of aliphatic epoxides 德美特 2021-11-05 CN disclosed
US-20160332952-A1 TERPENE-DERIVED ACIDS AND ESTERS AND METHODS FOR PREPARING AND USING SAME P2 SCIENCE, INC. 2016-11-17 US disclosed
WO-2015191706-A1 TERPENE-DERIVED COMPOUNDS AND METHODS FOR PREPARING AND USING SAME P2 SCIENCE, INC. (US) 2015-12-17 WO disclosed
WO-2015106293-A1 TERPENE-DERIVED ACIDS AND ESTERS AND METHODS FOR PREPARING AND USING SAME P2 SCIENCE, INC. (US) 2015-07-16 WO disclosed
US-20140357547-A1 PROCESS FOR THE PREPARATION OF METHOXYMELONAL GIVAUDAN S.A. (CH) 2014-12-04 US disclosed
US-20140357547-A1 PROCESS FOR THE PREPARATION OF METHOXYMELONAL GIVAUDAN S.A. (CH) 2014-12-04 US disclosed
WO-2013053102-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2013-04-18 WO disclosed
EP-0127672-A1 PROCESS FOR PREPARATION OF ARYLTERPENOID INSECT MATURATION INHIBITORS SCM CORPORATION (US) 1984-12-12 EP disclosed
US-4484007-A Process for preparation of arylterpenoid insect maturation inhibitors SCM CORPORATION (US) 1984-11-20 US disclosed
WO-1984002337-A1 PROCESS FOR PREPARATION OF ARYLTERPENOID INSECT MATURATION INHIBITORS SCM CORP (US) 1984-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357547-A1 PROCESS FOR THE PREPARATION OF METHOXYMELONAL MSMO1, CYP17A1, CYP51A1 CYP3A4 74/4885ALDH1A1 736/4885TDP1 2155/4885
US-20160332952-A1 TERPENE-DERIVED ACIDS AND ESTERS AND METHODS FOR PREPARING AND USING SAME GGPS1, CYP51A1, LSS CYP3A4 89/4885ALDH1A1 761/4885TDP1 3561/4885
US-20220169601-A1 PROCESS FOR PERHYDROLYSIS OF ALIPHATIC EPOXIDES HAO2, HPD, HOGA1 CYP3A4 637/4885ALDH1A1 350/4885TDP1 1326/4885
US-11512050-B2 Process for perhydrolysis of aliphatic epoxides HAO2, HPD, HOGA1 CYP3A4 637/4885ALDH1A1 350/4885TDP1 1326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.